The market continues to trade deeper in overbought territory based on most traditional valuation met

Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,

NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde &

There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that ma

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

On Thursday, Roche Holdings AG RHHBY agreed to acquire 89bio, Inc. ETNB for $2.4 billion. 89Bio is a

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t

Roche has agreed to acquire American biotech 89bio in a transaction worth up to $3.5 billion, as it

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating 89bio (Nasdaq: ETNB) for possible breach

The deal seeks to strengthen the drugmaker's pipeline by adding an experimental drug for an obesity

Roche said on Thursday it agreed to acquire U.S. biotech firm 89bio ETNB.O for up to $3.5 billion to

– 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cas

89bio, Inc. (NASDAQ:ETNB ) Cantor Global Healthcare Conference 2025 September 4, 2025 11:30 AM EDT C

SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ET

89bio, Inc. (NASDAQ:ETNB ) Citi's Biopharma Back to School Conference September 3, 2025 11:15 AM EDT

Pegozafermin is ETNB's long-acting FGF21 analog. It's undergoing three Phase 3 trials. Two of those

89bio (ETNB) Q2 R&D Jumps 131%

  Tuesday's session saw 211 companies set new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Monday